Corporate Presentation dated March 5, 2025

Presentation by Dr. Kevin Garey at the Peggy Lillis Foundation Inaugural CDI Scientific Symposium with Phase 2 Clinical Trial Update

Presentation at ICDS Conference, September 2024, Microbiome Results from the phase 2, randomized, double-blind study of ibezapolstat compared with vancomycin for the treatment of Clostridioides difficileinfection

Smits presentation at ICDS Conference, September 2024 “Structure of the replicative polymerase PolC in complex with the anti-CDI agent ibezapolstat and a related inhibitor.”

Presentation: Anaerobe Conference 2024, Garey, Phase 2 Microbiome Data

Presentation by Kevin Garey, PharmD, MS, FIDSA, Professor and Chair, University of Houston College of Pharmacy, at ESCMID (April 2024) entitled “ Efficacy and safety of ibezapolstat compared with vancomycin for the treatment of Clostridioides difficile infection: a phase 2, randomized, double-blind study

Golf Coast Consortia AMR Conference Presentation of Ph2b Comparative Microbiology and Microbiome Data, by Dr. Kevin Garey, et. al., January 2024

42nd Annual JP Morgan Healthcare Conference Presentation by David P. Luci, President & CEO

ID Week Presentation by Dr. Michael Silverman and Dr. Kevin Garey Ibezapolstat October 2023

ID Week Presentation Dr. Kevin Garey “Gram Positive Selective Spectrum Activity of Ibezapolstat October 2023

• 1
• 2
• Next »